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Abstract
Summary Predictors of 25(OH)D3 half-life were factors asso-
ciated with vitamin D metabolism, but were different between
people in The Gambia and the UK. Country was the strongest
predictor of plasma 25(OH)D concentration, probably as a
marker of UVB exposure. 25(OH)D3 half-life may be applied
as a tool to investigate vitamin D expenditure.
Introduction The aim of this study was to investigate predictors
of 25(OH)D3 half-life and plasma 25(OH)D concentration.
Methods Plasma half-life of an oral tracer dose of deuterated-
25(OH)D3 was measured in healthy men aged 24–39 years,
resident in The Gambia, West Africa (n=18) and in the UK
during the winter (n=18), countries that differ in calcium
intake and vitamin D status. Plasma and urinary markers of
vitamin D, calcium, phosphate and bone metabolism, nutrient
intakes and anthropometry were measured.
Results Normally distributed data are presented as mean (SD)
and non-normal data as geometric mean (95 % CI). Gambian
compared to UK men had higher plasma concentrations of
25(OH)D (69 (13) vs. 29 (11) nmol/L; P<0.0001);
1,25(OH)2D (181 (165, 197) vs. 120 (109, 132)pmol/L;
P<0.01); and parathyroid hormone (PTH) (50 (42, 60) vs. 33
(27, 39); P<0.0001). There was no difference in 25(OH)D3
half-life (14.7 (3.5)days vs. 15.6 (2.5)days) between countries
(P=0.2). In multivariate analyses, 25(OH)D, 1,25(OH)2D, vi-
tamin D binding protein and albumin-adjusted calcium (Caalb)
explained 79% of variance in 25(OH)D3 half-life in Gambians,
but no significant predictors were found in UK participants. For
the countries combined, Caalb, PTH and plasma phosphate
explained 39 % of half-life variability. 1,25(OH)2D, weight,
PTH and country explained 81 % of variability in 25(OH)D
concentration; however, country alone explained 74 %.
Conclusion Factors known to affect 25(OH)D metabolism pre-
dict 25(OH)D3 half-life, but these differed between countries.
Country predicted 25(OH)D, probably as a proxy measure for
UVB exposure and vitamin D supply. This study supports the
use of 25(OH)D half-life to investigate vitamin D metabolism.
Keywords 24,25(OH)2D . Gambia . Half-life . VitaminD
binding protein . VitaminDmetabolism
Introduction
Vitamin D is essential for human health, and a growing body
of evidence links vitamin D status to health outcomes beyond
those associated with the musculoskeletal system [1]. Func-
tional biomarkers are required to determine the adequacy of
vitamin D status and to determine physiological requirements
during growth, pregnancy or ageing and how requirements
may be modified by ethnicity, sex, and disease or body com-
position. Biomarkers are also required to address specific
questions such as elucidating the vitamin D-response relation-
ship and its functional outcomes. Plasma 25-hydroxyvitamin
D (25(OH)D) concentration is the most commonly usedmark-
er of vitamin D status. It is determined by endogenous vitamin
D synthesis and dietary intake, conversion into 25(OH)D and,
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finally, distribution and usage (metabolism and excretion).
The concentration of 25(OH)D in plasma is largely unregu-
lated, and it has a relatively long half-life of 2–3 weeks [2–5].
Plasma 25(OH)D half-life, as a marker of vitamin D usage,
may be useful for elucidating the determinants of the vitamin
D dose-response relationship and for examining relationships
between vitamin D, calcium, phosphate metabolism and bal-
ance, their regulating hormones and other factors related to
vitamin Dmetabolism. In clinical and animal studies that used
radiolabelled isotopes, lower plasma 1,25(OH)2D [6, 7], lower
parathyroid hormone (PTH) [8] and calcium supplementation
were associated with a longer half-life [6, 8]. Fibre intake [9]
and vitamin D binding protein (DBP) concentration and ge-
notype may also influence 25(OH)D half-life [10].
We previously described a method to measure 25(OH)D
half-life [5, 10] that uses stable isotope tracers. Here, we report
an investigation of 25(OH)D3 half-life as a biomarker of
25(OH)D expenditure by examining relationships between
half-life and known drivers of vitamin D metabolism in two
distinct populations. The study was performed in healthy men
resident in a rural area of The Gambia, West Africa, and in
Cambridge, UK, populations known to differ in vitamin D
status, calcium intake and markers of vitamin D metabolism
(e.g. 1,25(OH)2D and PTH) [11]. We tested the hypothesis
that 25(OH)D half-life in these populations differs due to these
differences in dietary calcium intake and vitamin D supply.
We also investigated predictors of plasma 25(OH)D concen-
tration using the same variables.
Subjects and methods
Study setting
Detailed descriptions of the study design and subject charac-
teristics were published previously [10]. In short, the studywas
performed at two centres: MRC Keneba, a rural field station in
The Gambia (latitude 13° N), and at MRC Human Nutrition
Research (HNR), Cambridge, UK (latitude 52° N). The study
was conducted according to the guidelines laid down in the
Declaration of Helsinki, and procedures involving the partici-
pants were approved by the joint Gambian Government-MRC
ethics committee and the UKNational Research Ethics Service
(NRES) Cambridge committee, respectively. Trained staff ex-
plained the study to the participants, and informed written
consent was obtained. There is year-round ability to synthesise
vitamin D in The Gambia where field work was performed at
the end of the dry season, in May and June 2010. In the UK,
study procedures were carried out between January and April
2011, when there is little or no cutaneous synthesis of vitamin
D and an exclusion criterion was recent (previous 3 months) or
planned (during study period) travel to tropical or subtropical
countries or high-altitude areas.
Participants
Participants (n=36) were healthy, nonsmoking males, aged
between 25 and 39 years. Exclusion criteria were recent illness
(within 2 weeks); a broken bonewithin the last 3 years; known
bone, kidney or liver disease; taking any prescription medi-
cines; or haemoglobin less than 10 g/dL. All Gambian partic-
ipants were of Mandinka ethnicity (defined by self-reported
ethnicity of the father), and UK subjects were all self-
classified as white.
Study protocols
The same study protocols were followed in The Gambia
and the UK. On day 1 and day 21 of the study, and
following an overnight fast and voiding of the first
morning urine, a 2-h fasting urine [5] was collected from
approximately 7:00 a.m. A blood sample was collected
after 1 h. Height (Leicester Stadiometer, Chasmoors Ltd,
London, UK), weight (Tanita HD305 scale, Tanita,
Amsterdam, The Netherlands) and body composition by
bioelectrical impedance (Tanita BC418-MA Tanita,
Amsterdam, The Netherlands) were measured. On day
1, and after completion of the urine collection, partici-
pants were given an oral tracer dose of 40 nmol (16 μg)
of stable isotope-labelled 25(OH)D3 (d3-25(OH)D3) (deu-
terated (6, 19, 19) 25-hydroxy vitamin D3) (product
number 705888; 97 atom %; purity 98 %; Sigma-Al-
drich, Poole, UK) dissolved in vegetable oil with a
standard breakfast [10]. Fasted blood samples were col-
lected into tubes containing lithium heparin anticoagulant
on day 6 and (±2 days) days 9, 21, 24, 27, 30 and 33 for
measurement of the plasma tracer concentration for the
calculation 25(OH)D3 half-life [5, 10].
Dietary nutrient intakes were quantitatively assessed
with methods appropriate to each country. In The Gambia,
trained field workers weighed all meals, snacks and drinks
consumed over 2 days and coding of the dietary records
was performed using The Gambian Food Composition
Tables [12]. In the UK, a 4-day food diary was completed
during one weekend and two week days. All dietary data
were entered at MRC HNR using DINO (Diet In Nutri-
ents Out), an in-house analysis program to calculate nutri-
ent intakes [13].
Sample processing and laboratory analysis
Blood was collected into tubes containing either ethylenedi-
aminetetraacetic acid (EDTA) or lithium heparin anticoagu-
lant (S-Monovettes, Sarstedt Ltd, Leicester, UK) and plasma
separated by centrifugation at 1800g for 20 min at 4 °C.
Samples were stored at −70 °C. Collected urine was mixed
thoroughly and acidified (Hydrochloric acid, 10 mL/L Fisher
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Scientific, Loughborough, UK), and aliquots were stored at
−20 °C. Gambian samples were shipped for analysis to MRC
HNR, Cambridge, on dry ice.
Plasma calcium, phosphate, creatinine and albumin
and urinary calcium (uCa), urinary phosphate (uP) and
urinary creatinine (uCr) were measured on the Kone Lab
20i clinical chemistry analyser platform (Kone, Espoo,
Finland). Plasma osteocalcin (OC) and bone alkaline
phosphatase (BAP) were measured on the DiaSorin
Liason platform (DiaSorin Ltd., Dartford, UK).
Carboxy-terminal cross-linking telopeptide of type I col-
lagen (β-CTX) was measured by ELISA (Immunodiag-
nostics Systems Ltd., Tyne & Wear, UK). EDTA plasma
was used for analysis of PTH by immunoassay
(Immulite, Siemens Healthcare Diagnostics Ltd,
Camberley, UK), and C-terminal fibroblast growth
factor-23 (FGF23) was analysed using a second-
generation C-terminal, two-site enzyme-linked immuno-
sorbent assay (Immutopics Inc., San Clemente, CA).
Plasma 1,25(OH)2D was measured with a radioimmuno-
assay (IDS Ltd., Tyne and Wear, UK). DBP was mea-
sured by radial immunodiffusion assay with polyclonal
antibody [14], and 24,25(OH)2D was analysed by UPLC-
MS/MS (method modified from [15], both at KU Leu-
ven, Belgium).
Assay performance at MRC HNR was monitored using kit
and in-house controls and under strict standardisation accord-
i ng t o ISO 9001 : 2000 . Qua l i t y a s s u r a nc e o f
25(OH)D,1,25(OH)2D and PTH assays was performed as part
of the Vitamin D External Quality Assessment Scheme (www.
deqas.org) and the National External Quality Assessment
Scheme (www.ukneqas.org.uk) and was within accepted
limits. In addition, an aliquot of a pooled plasma sample was
assayed in each batch to monitor possible drift over time and
to provide running quality assurance for analytes where no
external reference material was available. Further details of
assay performance are described in [16].
Mass spectrometry
25(OH)D2, 25(OH)D3, and d3-25(OH)D3 were measured by
UPLC-MS/MS as described previously [10]. Intra- and inter-
assay coefficients of variation were <10 % for all analytes.
Total 25(OH)Dwas calculated from the sum of 25(OH)D2 and
25(OH)D3.
Data analysis
25(OH)D3 half-life was calculated from the slope of plasma
d3-25(OH)D3 disappearance using the line of best fit of the
natural log of d3-25(OH)D3 concentration against time [10].
One additional Gambian participant was removed from the
analysis because 25(OH)D3 half-life values were more than 3
interquartile ranges beyond the 75th centile [10] and had a
major impact on relationships between half-life and other
variables when analysed together with the remaining partici-
pants (n=36). Body mass index was calculated as weight
divided by the square of height (kg/m2). Plasma calcium was
adjusted for albumin (Caalb) by normalising to an albumin
concentration of 40 g/L and a correction factor of ±0.02 mmol
calcium/g albumin above or below 36 g/L [16]. Fasting 2-h
uCa and uP were divided by uCr to derive uCa/uCr and uP/
uCr ratios. Statistics were performed in Stata 11 (Stata
Corp, TX, USA). Normally distributed data are presented
as means and standard deviation (SD). Skewed data were
log-transformed and are presented as geometric means
and 95 % confidence interval. There were no differences
between day 1 and day 21 values of plasma and urinary
analytes as tested with paired Student’s t tests, so subse-
quent analysis was performed with the mean values.
Unpaired Student’s t tests were used to test for differ-
ences between populations (Table 1). Statistical analyses
were performed on countries separately, due to clustering
of data and country-specific associations, and subse-
quently with data for countries combined with the inclu-
sion of country in the model. In the combined country
models, a country×independent-variable interaction was
also tested.
Simple regression was used to evaluate anthropometric,
biochemical and dietary predictors of 25(OH)D3 half-life
(Table 2) or 25(OH)D plasma concentration (Table 3) for
the countries separately and for the countries combined.
Multiple linear regression was used to identify variables
that independently predicted 25(OH)D3 half-life (Table 4)
or 25(OH)D3 (Table 5). Throughout, the same full starting
models were used with variables for inclusion selected a
priori on the basis of a theoretical biological mechanism
and/or a significant relationship as assessed with simple
regression. These variables were 25(OH)D, 1,25(OH)2D,
DBP, Caalb, weight, age, PTH, FGF23, plasma phosphate
and dietary calcium intake. Dietary phosphate intake and
the plasma concentration of 24,25(OH)2D were not in-
cluded in multiple regression because of their highly
significant and strong correlation with calcium intake
(phosphate intake r=0.87, P<0.0001 for countries com-
bined) and plasma 25(OH)D (24,25(OH)2D r=0.94,
P<0.0001 for countries combined), respectively. Variables
that were not significant and did not reduce variance were
removed, and the final models were chosen based on
robustness after the examination of relationships between
all variables. Regression coefficients (slope) represent the
change in 25(OH)D3 half-life or 25(OH)D plasma con-
centration for a 1-unit change in the predictor variable.
For log-transformed variables (1,25(OH)2D, PTH, FGF23,
uCa/uCr, uP/uCr, and plasma BAP, OC and β-CTX), the
regression coefficient represents the change in 25(OH)D3
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half-life or 25(OH)D plasma concentration for a 100 %
change in the predictor variable. Relationships were con-
sidered significant where P<0.05, and a trend for a rela-
tionship was noted where P≥0.05 and P<0.1.
Results
Country comparisons
Anthropometric, biochemical and dietary data are shown in
Table 1. Gambian participants were significantly shorter and
lighter than UK participants and had lower fat mass and fat-
free mass. Plasma 25(OH)D, 1,25(OH)2D, 24,25(OH)2D,
PTH and FGF23 concentrations were higher and plasma
DBP, Caalb and plasma phosphate were not different in Gam-
bian compared to UK participants. Markers of bone resorption
and formation were also higher in Gambian participants.
Gambian macro- and micronutrient intakes were generally
lower than those in the UKwith the exception of carbohydrate
and magnesium which were significantly higher. Consistent
with the lower dietary calcium and phosphate intakes, fasting
2-h urinary excretions in The Gambia were lower than those in
the UK. Mean 25(OH)D3 half-life was 14.7 (3.5)days and
15.6 (2.5)days in The Gambia and UK, respectively, and was
not significantly different between countries (difference
0.9 days; P=0.2) [10].
Predictors of 25(OH)D3 half-life
In Gambian participants, 25(OH)D3 half-life was nega-
tively associated with Caalb and positively associated
with age and DBP (Table 2) in simple regression models.
There were trends towards a negative association with
PTH (P=0.09) and positive with uP/uCr (P=0.08). In
contrast, in the UK participants in simple regression
models, none of the measured variables were significant-
ly associated with 25(OH)D3 half-life. With the countries
combined, where the country was also included in the
model, Caalb was negatively associated and age, DBP
and plasma phosphate were positively associated with
25(OH)D3 half-life. Near-significant relationships were
also observed with PTH (inversely) and uP/uCr (a posi-
tive association); in none of these models was country a
significant predictor of 25(OH)D3 half-life. However, the
pattern of the relationship between half-life and both
Caalb and age differed between countries. There were
significant country×age (P=0.03) and country×Caalb in-
teractions (P=0.006) such that the positive association
with age and negative association with Caalb was of a
greater magnitude in the Gambians and not significant in
the UK participants.
Results of the multivariate model (Table 3) were partly
consistent with simple regression analysis. Caalb and
1,25(OH)2D negatively predicted and 25(OH)D and DBP
positively predicted 25(OH)D3 half-life in Gambians. Togeth-
er, these variables explained 79 % (adjusted R2) of the varia-
tion in 25(OH)D3 half-life. There were no significant associ-
ations in UK participants (Table 3). In the model for the
Table 1 Participant age, anthropometric data, biochemistry and nutrient







Age, years 29.2 (3.2) 29.3 (4.4) 1.0
Weight, kg 64.5 (8.3) 73.3 (10.9) 0.01
Height, m 1.74 (0.06) 1.80 (0.07) 0.009
BMI, kg/m2 21.3 (2.0) 22.6 (2.3) 0.08
Fat mass, kg 7.5 (2.6) 10.3 (4.3) 0.02
Fat-free mass, kg 55.7 (6.7) 62.6 (8.0) 0.009
Biochemistry
25(OH)D2, nmol/L 0.6 (0.2) 2.1 (1.0) <0.0001
25(OH)D3, nmol/L 68.4 (13.1) 26.5 (10.8) <0.0001
25(OH)D, nmol/L 69.0 (13.2) 28.6 (11.0) <0.0001
1,25(OH)2D, pmol/L
b 181 (165, 197) 120 (109, 132) <0.0001
24,25(OH)2D, nmol/L 6.5 (1.3) 1.9 (1.4) <0.0001
DBP, mg/L 259 (33) 268 (23) 0.4
Albumin, g/L 36.4 (2.2) 41.0 (2.4) <0.0001
Caalb, mmol/L 2.25 (0.06) 2.27 (0.06) 0.2
Phosphate, mmol/L 1.04 (0.14) 1.05 (0.10) 0.9
PTH, ng/Lb 50.1 (41.9, 60.0) 32.8 (27.4, 39.3) <0.01
FGF23, RU/mLb 79.2 (58.6, 106.9) 57.0 (52.5, 62.0) 0.03
Plasma BAP, μg/Lb 17.3 (12.8, 23.3) 11.8 (10.1, 13.9) 0.02
Plasma OC, μg/Lb 15.0 (12.7, 17.6) 10.8 (9.3, 12.6) 0.004
Plasma β-CTX, μg/Lb 1.0 (0.9, 1.2) 0.6 (0.5, 0.7) <0.0001
uCa/uCr, mmol/mmolb 0.06 (0.04, 0.09) 0.17 (0.13, 0.26) <0.0001
uP/uCr, mmol/mmolb 0.73 (0.59, 0.90) 0.99 (0.83, 1.17) 0.02
Nutrient intakec
Energy, kJ/day 8267 (2383) 9804 (1931) 0.04
Fat, g/day 42 (17) 94 (27) <0.001
Protein, g/day 68 (26) 90 (19) 0.005
Carbohydrate, g/day 358 (115) 281 (60) 0.02
Calcium, mg/day 358 (177) 1087 (248) <0.0001
Phosphate, mg/day 803 (332) 1603 (300) <0.0001
Magnesium, mg/day 506 (222) 361 (94) 0.02
DBP vitamin D binding protein, Caalb plasma calcium corrected for
albumin, PTH parathyroid hormone, FGF23 fibroblast growth factor
23, BAP bone alkaline phosphatase, OC osteocalcin, β-CTX β-carboxy-
terminal collagen crosslinks, uCa/uCr creatinine corrected fasting 2-h
urinary Ca, uP/uCr creatinine corrected fasting 2-h urinary phosphate
a Country differences as tested by unpaired, two-tailed Student’s t test
b Data are presented as mean (SD) or geometric mean (95 % CI) of
samples collected on day 1 and day 21
cDaily nutrient intakes were assessed by 2-day weighed dietary assess-
ment in The Gambia and 4-day food diary in the UK
1140 Osteoporos Int (2015) 26:1137–1146
Table 2 Regression analysis of 25(OH)D3 half-life and other variables by country and for the countries combined
The Gambia UK Countries combined and corrected for countrya
Slope (95 % CI) P value Slope (95 % CI) P value Slope (95 % CI) P value
Age and anthropometry
Age, years 0.63 (0.16, 1.10) 0.01 0.07 (−0.23, 0.37) 0.6 0.27 (0.002, 0.54) 0.05b
Weight, kg 0.09 (−0.13, 0.31) 0.4 −0.02 (−0.14, 0.10) 0.7 0.02 (−0.09, 0.13) 0.7
BMI, kg/m2 0.34 (−0.61, 1.28) 0.5 −0.19 (−0.75, 0.37) 0.5 0.03 (−0.48, 0.54) 0.9
Fat mass, kg 0.14 (−0.56, 0.86) 0.7 −0.02 (−0.33, 0.28) 0.9 0.02 (−0.28, 0.33) 0.9
Fat-free mass, kg 0.12 (−0.15, 0.39) 0.4 −0.03 (−0.19, 0.14) 0.7 0.04 (−0.11, 0.18) 0.6
Markers of vitamin D, Ca and P metabolism
25(OH)D, nmol/L 0.09 (−0.04, 0.22) 0.2 −0.02 (−0.14, 0.10) 0.7 0.04 (−0.04, 0.13) 0.3
1,25(OH)2D, pmol/L
c 4.70 (−5.49, 14.88) 0.3 −1.67 (−8.48, 5.12) 0.6 1.27 (−4.54, 7.08) 0.7
24,25(OH)2D, nmol/L 0.64 (−0.72, 2.01) 0.3 −0.09 (−1.04, 0.86) 0.8 −0.26 (−0.53, 1.05) 0.5
DBP, mg/L 0.06 (0.14, 0.11) 0.01 0.004 (−0.05, 0.06) 0.9 0.04 (0.007, 0.08) 0.02
Albumin, g/L −0.18 (−1.03, 0.67) 0.7 0.25 (−0.28, 0.78) 0.3 0.06 (−0.41, 0.53) 0.8
Caalb, mmol/L −44.6 (−65.5, −23.6) <0.0001 −1.31 (−23.6, 21.0) 0.9 −23.0 (−39.3, −6.58) 0.007b
Phosphate, mmol/L 8.37 (−4.07, 20.8) 0.2 9.20 (−2.85, 21.26) 0.1 8.66 (0.43, 16.8) 0.04
PTH, ng/Lc −4.06 (−8.87, 0.71) 0.09 −1.42 (−5.02, 2.18) 0.4 −2.73 (−5.59, 0.13) 0.06
FGF23, RU/mLc 0.19 (−2.92, 3.31) 0.9 −0.71 (−8.66, 7.24) 0.9 0.13 (−2.32, 2.59) 0.9
uCa/uCr, mmol/mmolc −0.78 (−2.97, 1.40) 0.5 −1.21 (−3.38, 0.96) 0.3 −0.92 (−2.38, 0.53) 0.2
uP/uCr, mmol/mmolc 3.46 (−0.51, 7.42) 0.08 1.33 (−2.50, 5.16) 0.5 2.64 (−0.006, 5.28) 0.05
Markers of bone metabolism
Plasma BAP, μg/Lc −0.94 (−4.05, 2.17) 0.5 1.10 (−3.01, 5.22) 0.6 −0.49 (−2.75, 1.78) 0.7
Plasma OC, μg/Lc −0.26 (−6.07, 5.54) 0.9 −0.49 (−4.83, 3.85) 0.8 −0.37 (−3.82, 3.09) 0.8
Plasma β-CTX, μg/Lc −2.02 (−8.30, 4.27) 0.5 0.47 (−3.57, 4.50) 0.8 −0.64 (−4.12, 2.83) 0.7
Nutrient intake
Calcium intake, mg/day 0.003 (−0.007, 0.14) 0.4 0.003 (−0.002, 0.008) 0.2 0.004 (−0.001, 0.008) 0.1
Phosphate intake, mg/day 0.003 (−0.002, 0.01) 0.2 0.00003 (−0.004, 0.004) 1.0 0.002 (−0.002, 0.005) 0.3
Italicized values show significant (P<0.05) associations with 25(OH)D3 half-life or a trend for an association (P<0.1, ≥0.5)
a Country was a not significant predictor for any variable
b There were significant country×age (P=0.03) and country×Caalb (P=0.006) interactions
c Log-transformed variables. Coefficients represent change in 25(OH)D3 half-life for 100 % change in the predictor variable
Table 3 Predictors of 25(OH)D3 half-life in Gambian and UK participants and for countries combined in multivariate regression model
Gambia (n=18) UK (n=18) Countries combined (n=36)
Slope (95 % CI) P value Slope (95 % CI) P value Slope (95 % CI) P value
25(OH)D 0.12 (0.04, 0.19) 0.004 −0.02 (−0.18, 0.14) 0.8
1,25(OH)2D
a −6.33 (−12.1, −0.54) 0.04 −1.3 (−9.6, 7.0) 0.7
DBP 0.04 (0.01, 0.07) 0.009 −0.003 (−0.07, 0.07) 0.9
Caalb −44.5 (−60.7, −28.2) <0.0001 −2.56 (−30.5, 25.4) 0.8 −24.2 (−38.3, −10.0) 0.001
PTHa −3.20 (−5.53, −0.86) 0.009
Plasma phosphate 8.38 (1.62, 15.14) 0.02
Country 0.9
a Log-transformed variables. Coefficients represent change in 25(OH)D3 half-life for 100 % change in the predictor variable
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countries combined, Caalb and PTH were negatively associat-
ed and plasma phosphate positively associated with half-life
(Table 3). Country was nonsignificant.
In simple and multivariate regression, we obtained similar
results if pH-adjusted ionised calcium or plasma calcium
(independent of plasma albumin) were used instead of Caalb
Table 4 Regression analysis of plasma 25(OH)D and other variables by country and for the countries combined
The Gambia UK Countries combined and corrected for countrya
Slope (95 % CI) P value Slope (95 % CI) P value Slope (95 % CI) P value
Age and anthropometry
Age, years −0.17 (−2.33, 1.99) 0.9 0.71 (−0.57, 1.99) 0.3 0.40 (−0.71, 1.51) 0.5
Weight, kg 0.53 (−0.27, 1.32) 0.2 0.25 (−0.27, 0.76) 0.3 0.35 (−0.76, 0.77) 0.1
BMI, kg/m2 1.83 (−1.63, 5.29) 0.3 0.74 (−1.73, 3.22) 0.5 1.19 (−0.77, 3.16) 0.2
Fat mass, kg 0.31 (−2.35, 2.98) 0.8 0.72 (−0.58, 2.01) 0.3 0.61 (−0.58, 1.79) 0.3
Fat-free mass, kg 0.72 (−0.25, 1.69) 0.1 0.25 (−0.47, 0.96) 0.5 0.44 (−0.12, 1.00) 0.1
Markers of vitamin D, Ca and P metabolism
25(OH)D, nmol/L – – – – – –
1,25(OH)2D, pmol/L
b 29.8 (−5.97, 65.6) 0.1 20.9 (−6.98, 48.8) 0.1 25.0 (3.72, 46.3) 0.02
24,25(OH)2D, nmol/L 6.26 (2.20, 10.3) 0.005 6.94 (5.02, 8.87) <0.0001 6.62 (4.52, 8.72) <0.0001
DBP, mg/L 0.04 (−0.16, 0.25) 0.7 −0.11 (−0.35, 0.13) 0.4 −0.006 (−0.16, 0.14) 0.9
Albumin, g/L −3.30 (−5.96, −0.63) 0.02 0.51 (−1.88, 2.90) 0.7 −1.22 (−3.03, 0.59) 0.2c
Caalb, mmol/L 2.46 (−115, 120) 1.0 −45.1 (−139.8, 49.7) 0.3 −21.3 (−93.2, 50.7) 0.6
Plasma phosphate, mmol/L 12.5 (−36.3, 61.4) 0.6 −11.5 (−68.1, 45.0) 0.7 4.38 (−30.3, 39.1) 0.8
PTH, ng/Lb −8.62 (−27.6, 10.4) 0.4 −11.4 (−26.3, 3.44) 0.1 −10.0 (−21.4, 1.36) 0.08
FGF23, RU/mLb −5.34 (16.6, 5.94) 0.3 −6.98 (−41.6, 27.6) 0.7 −5.46 (−15.0, 4.08) 0.3
uCa/uCr, mmol/mmolb −1.61 (−9.86, 6.64) 0.7 −3.81 (−13.5, 5.87) 0.4 −2.32 (−8.18, 3.53) 0.4
uP/uCr, mmol/mmolb −0.55 (−16.9, 15.8) 0.9 −13.6 (−29.0, 1.78) 0.08 −5.61 (−16.5, 5.30) 0.3
Markers of bone metabolism
Plasma BAP, μg/Lb 3.90 (−7.66, 15.5) 0.5 7.38 (−10.4, 25.1) 0.4 4.68 (−4.16, 13.5) 0.3
Plasma OC, μg/Lb −10.3 (−31.3, 10.7) 0.3 3.13 (−15.8, 22.1) 0.7 −3.98 (−17.6, 9.61) 0.6
Plasma β-CTX, μg/Lb 5.20 (18.4, 28.8) 0.6 −1.82 (−19.5, 15.8) 0.8 1.31 (−12.5, 15.1) 0.8
Nutrient intake
Calcium intake, mg/day −0.007 (−0.05, 0.03) 0.7 0.0007 (−0.02, 0.02) 0.9 −0.002 (−0.02, 0.02) 0.9
Phosphate intake, mg/day 0.01 (−0.009, 0.03) 0.2 0.002 (−0.02, 0.02) 0.8 0.007 (−0.006, 0.02) 0.3
Italicized values show significant (P<0.05) associations with 25(OH)D3 or a trend for an association (P<0.1, ≥0.5)
a Country was a significant predictor for all variables (P<0.0001) with the exception of 24,25(OH)2D
b Log-transformed variables. Coefficients represent change in 25(OH)D plasma concentration for 100 % change in the predictor variable
c There was a significant country×albumin interaction (P=0.03)
Table 5 Predictors of plasma 25(OH)D in Gambian and UK participants and for countries combined in multivariate regression model
Gambia (n=18) UK (n=18) Countries combined (n=36)
Slope (95 % CI) P value Slope (95 % CI) P value Slope (95 % CI) P value
1,25(OH)2D
a 33.2 (0.13, 66.3) 0.05 21.3 (−3.50, 46.2) 0.09 29.3 (9.89, 48.8) 0.004
Caalb −68.3 (−152, 15.8) 0.1
PTHa −15.7 (33.8, 2.4) 0.09 −14.6 (−28.4, −0.76) 0.04 −9.76 (−19.6, 0.12) 0.05
FGF23a −10.5 (−21.4, 0.3) 0.06
Weight 0.45 (0.08, 0.82) 0.02
Country <0.0001
a Log-transformed variables. Coefficients represent change in 25(OH)D plasma concentration for 100 % change in predictor variable
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for countries analysed separately and combined (data not
shown).
Predictors of 25(OH)D
There were few significant associations with 25(OH)D in
simple regression models: 24,25(OH)2D was positively
associated with 25(OH)D in both countries and for the
countries combined. Plasma albumin inversely predicted
25(OH)D in Gambians, and there were trends for a positive
association with 1,25(OH)2D (P=0.097) in Gambians and a
negative association with uP/uCr (P=0.08) in UK partici-
pants (Table 4). When the countries were combined, there
was a positive association with 1,25(OH)2D and a trend
towards a negative association with PTH (P=0.08)
(Table 4); country was a highly significant predictor of
25(OH)D (The Gambia>UK, P<0.0001) in all models with
the exception of 24,25(OH)2D. There was a significant
country×albumin interaction (P=0.03), such that there
was a strong negative association with albumin in the
Gambians and a nonsignificant positive association in the
UK participants.
In country-specific multivariate models, 1,25(OH)D2
positively predicted 25(OH)D, and there was a trend for
inverse associations with FGF23 and PTH for Gambians
(Table 5). In the UK, there was a significant inverse
association with PTH, together with near-significant nega-
tive and positive associations with Caalb and 1,25(OH)2D,
respectively (Table 5). When the countries were combined,
country was the strongest predictor of 25(OH)D, account-
ing for 74 % (adjusted R2) of the variation in 25(OH)D.
However, PTH negatively predicted and 1,25(OH)2D and
weight positively predicted 25(OH)D and, together with
country, accounted for 81 % of the variation (Table 5).
There were no significant interactions with country.
Predictors of 24,25(OH)2D
The only consistently significant predictor of 24,25(OH)2D
was 25(OH)D, and this was true when data for the countries
were combined (with country as a covariate) (coefficient,
0.08 nmol/L per 1 nmol/L change in 25(OH)D; P<0.0001)
and when analysed separately (The Gambia (coefficient,
0.06 nmol/L; P=0.005); the UK (coefficient, 0.11 nmol/L;
P<0.0001)). PTH also predicted 24,25(OH)2D in the coun-
tries combined and The Gambia (a 10 % change in PTH
predicts a 0.1 and 0. 2 nmol/L (P=0.03) decrease in
24,25(OH)2D, respectively). In multivariate models, there
were no predictors of 24,25(OH)2D other than 25(OH)D.
There were no associations with FGF23. In combined country
models, there were no country interactions.
Discussion
25(OH)D plasma concentration is a biomarker of vitamin D
status and reflects the balance between vitamin D supply from
cutaneous synthesis and diet, hepatic 25(OH)D production
and 25(OH)D expenditure, which represents primarily hy-
droxylation into 1,25(OH)2D and 24,25(OH)2D. Plasma
25(OH)D may also be influenced by the distribution volume,
storage and release of vitamin D and 25(OH)D from fat or
muscle [17]. Some of the mechanisms controlling 25(OH)D
status (whether production or utilisation) and their relative
importance in healthy people are not fully elucidated. The
measurement of 25(OH)D half-life provides a measure of
25(OH)D expenditure that allows investigation of factors that
influence plasma 25(OH)D concentration without the con-
founding contribution of newly synthesised 25(OH)D. We
have investigated the predictors of 25(OH)D3 half-life and
of plasma 25(OH)D in two distinct populations. In the Gambia
and when data for the countries were combined, we found that
the strongest and most consistent predictor of 25(OH)D3 half-
life was Caalb inversely, but PTH inversely and total
25(OH)D, 1,25(OH)2D, DBP and pP plasma phosphate pos-
itively predicted half-life in multivariate models. However,
predictors were different between countries and in models
for the countries combined. For total 25(OH)D, PTH was a
negative predictor, and 1,25(OH)2D and weight were positive
predictors, although country was the major influencing factor.
As with half-life, the predictors of plasma 25(OH)D differed
between countries. These data suggest that 25(OH)D half-life
is primarily predicted by factors associated with 25(OH)D
metabolism, whereas 25(OH)D is most strongly predicted by
country, probably as a proxy measure of vitamin D supply
from UVB exposure.
Plasma 25(OH)D half-life is likely to be determined by the
metabolism of 25(OH)D to downstreammetabolites and by its
catabolism, driven primarily by the activities of the enzymes
CYP27B1 (producing 1,25(OH)2D) and CYP24A1
(catabolising 25(OH)D and further downstream metabolites)
[6]. The activities of these enzymes are stimulated by a large
number of factors, the most important being increases in PTH
and 1,25(OH)2D and/or low plasma P. We observed associa-
tions between these factors and 25(OH)D3 half-life, although
these were not consistent between countries, possibly due to
genetic or environmental, especially dietary, differences. Low
dietary calcium intake [7] and low calcium bioavailability, due
to a high-fibre diet [9] or intestinal malabsorption [8, 18, 19],
were reported to be associated with a shorter half-life. This is
likely to be mediated through the PTH-CYP27B1-CYP24A1
axis, increasing the production of both 1,25(OH)2D and
24,25(OH)2D [7, 20]. In our study, dietary calcium intake
was 3-fold lower in Gambian compared to UK participants,
yet contrary to our expectations, there was no difference in
mean 25(OH)D3 half-life between the populations [10] and no
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association between half-life and calcium intake. This rela-
tionship may be difficult to prove in human studies over the
habitual range of calcium intake, particularly in populations
where there are other factors that may influence half-life and
may require a large sample size. In addition, we may not have
observed a difference in half-life between countries because of
population differences due to long-term adaptation of vitamin
D metabolism to either low vitamin D supply/high calcium
intake (UK) or high vitamin D supply/low calcium intake
(The Gambia). This may be due to genetic differences be-
tween populations, for example in DBP, vitamin D receptor or
hydroxylase enzymes, or the activity of the hydroxylase en-
zymes regulating 25(OH)D synthesis and catabolism into
1,25(OH)2D and 24,25(OH)2D and further downstream me-
tabolites. This could be investigated in future studies by the
assessment of downstream metabolites of the tracer
compound.
In this study, the strongest and most robust relationship
with half-life was observed with plasma Caalb although this
relationship was not observed in the UK participants when
analysed separately. This association, which was not a reflec-
tion of differences in plasma albumin concentration, is sur-
prising given that plasma calcium concentration is tightly
regulated and thus half-life is more likely to be strongly
associated with its regulators, PTH and 1,25(OH)2D. In addi-
tion, any relationship between plasma calcium and half-life
would have been expected, on a theoretic basis, to be positive,
with lower plasma calcium resulting in greater usage of
25(OH)D through the PTH-CYP27B1-CYP24A1 axis. The
importance of 1,25(OH)2D and PTH in the control of vitamin
D metabolism was shown previously in clinical and animal
studies. An increase in plasma 1,25(OH)2D and hyperpara-
thyroidism have been associated with an increase in 25(OH)D
expenditure, whereas hypoparathyroidism was associated
with a longer half-life [6]. Consistent with these results, we
found a negative relationship between PTH and 25(OH)D
half-life. A negative relationship between 1,25(OH)2D and
25(OH)D3 half-life was only observed in Gambians, possibly
because of the higher 1,25(OH)2D concentration in this pop-
ulation, likely related to their very low calcium intake.
The mechanisms of the reciprocal regulation of vitamin D
and phosphate metabolism are less well established than for
calcium [21]. Phosphate deficiency may stimulate CYP27B1,
leading to increased plasma 1,25(OH)2D [22], and high phos-
phate intake or plasma phosphate concentration is associated
with an elevated FGF23, which stimulates urinary phosphate
excretion and CYP24A1 activity and downregulates
CYP27B1. We found a positive relationship between plasma
phosphate, uP/uCr and 25(OH)D3 half-life, supporting a role
for phosphate in vitamin D metabolism. However, we did not
observe a relationship with c-terminal FGF23 or with dietary
phosphate intake. This lack of association was also observed
in a study in Gambian children where no relationship was
found between 25(OH)D half-life and active (intact) FGF23
[23]. We found that FGF23 was elevated in Gambians com-
pared to UK subjects. This may be due to low calcium intake
and/or high dietary phosphate/calcium ratio driving elevated
1,25(OH)2D. FGF23 is thought to regulate vitamin D metab-
olism in conjunction with PTH; FGF23 has been shown to
increase vitamin D receptor (VDR), calcium sensing receptor
and CYP24A1 expression and inhibit CYP27B1 expression
through which it suppresses plasma PTH and potentially
influences 25(OH)D half-life [24].
DBP concentration was positively associated with
25(OH)D3 half-life. DBP concentration and genotype may
affect vitamin D metabolism and function [25]. Vitamin D
metabolites are maintained in the circulation by their binding
to DBP. Higher circulating levels of DBP may reduce the
fraction of free-25(OH)D, and a longer half-life may be expect-
ed. Further, these relationships may be affected by DBP geno-
type that may [25] or may not [26] alter affinity. However, we
have shown earlier that the relationships between free-25(OH)D
and half-life are not different to those with 25(OH)D [10].
We also observed a positive association between 25(OH)D
and 25(OH)D3 half-life in Gambian participants. Early obser-
vations suggested an influence of 25(OH)D plasma status on
25(OH)D half-life, with more rapid turnover in vitamin D-
deplete subjects [27], but other studies have failed to repro-
duce these findings in normal and diseased subjects [8, 18].
Our results suggest, in Gambian participants at least, that a
higher plasma 25(OH)D concentration is associated with a
longer half-life, or that a longer half-life results in a higher
25(OH)D concentration. We found no relationships between
any of the anthropometric measures of size or fatness with
25(OH)D3 half-life (Tables 2 and 3).
The UK study was performed during winter and early
spring when vitamin D status is at its lowest. In contrast, there
is little seasonal change in the availability of vitamin D-
producing UVB radiation in The Gambia. Consequently, we
observed a highly significant difference in 25(OH)D plasma
concentration between countries such that country may act as
a surrogate for 25(OH)D in our analysis. Models that exam-
ined other predictors of 25(OH)D and that included country
had significantly different intercepts, reflecting the effect of
country (probably acting as a proxy for UVB exposure) on
25(OH)D. We did not formally assess skin pigmentation in
this study and therefore cannot comment on the effect of
differences in skin pigmentation on 25(OH)D production.
1,25(OH)2D was also a positive predictor of 25(OH)D and
may suggest that the greater supply of 25(OH)D permits
greater renal production of 1,25(OH)2D when calcium intake
is low. This was partly unexpected because 25(OH)D and
1,25(OH)2D do not generally correlate well, except when
25(OH)D is low [28], although others have reported a corre-
lation across a range of 25(OH)D plasma concentrations [28,
29]. The other major product of 25(OH)D is 24,25(OH)2D,
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and we found a very strong association between
24,25(OH)2D and its precursor, consistent with previous
studies [11, 31]. Multivariate models also indicated weight
as a significant positive independent predictor of 25(OH)D.
This is in contrast to other studies that have generally shown
poorer vitamin D status with increasing adiposity. In our
study, participants were relatively lean, and the BMI range
was narrow (BMI, 18–27 kg/m2). This may have precluded
seeing the inverse relationship reported between 25(OH)D
plasma concentration and adiposity [32]. If weight was
replaced with fat mass, then no significant association was
observed, but with fat-free mass, we observed a similar
response to the weight model.
Our study has a number of limitations. It was designed to
compare 25(OH)D3 half-life between different populations
and its predictors. We restricted participants to men within
relatively narrow age and BMI ranges, so we cannot report on
how the relationships may be different in women, in different
age groups or in overweight and obese individuals. Previous
reports of changes in half-life, or strong correlations between
half-life and other variables, have primarily been obtained
from studies with an acute change, such as a 1,25(OH)2D
challenge or a very high-fibre diet, or in a disease state [6–9,
33]. It may be more difficult to detect associations in a small
cross-sectional study such as this, especially in free-living
individuals. The relatively small sample size limited the power
of the statistical methods and means that the findings in this
study should be interpreted with a degree of caution. Studies
in larger cohorts are required to confirm the predictors of
25(OH)D half-life found here.
In conclusion, this study investigated predictors of the
plasma half-life of stable isotope-labelled 25(OH)D3 in free-
living individuals in two different countries. 25(OH)D3 half-
life was predicted by factors associated with vitamin D me-
tabolism (25(OH)D, 1,25(OH)2D, DBP, plasma phosphate
and PTH), although an inverse association with Caalb was
found. There were differences between countries in factors
predicting 25(OH)D3 half-life, and it is perhaps surprising,
given the large differences in calcium intake and 1,25(OH)2D
plasma concentration, that there was not a significant differ-
ence in 25(OH)D3 half-life between countries. This may sug-
gest a degree of adaptation, or regulation of 25(OH)D3 half-
life, either through expression of vitamin D hydroxylases or
because of genetic differences. In contrast, 25(OH)D was
primarily predicted by country, probably reflecting differences
in UVB exposure between the UK in winter and The Gambia.
25(OH)D half-life has value as a marker of 25(OH)D expen-
diture that can disentangle the effects of vitamin D supply and
utilisation. An understanding of factors that affect 25(OH)D
expenditure are required to determine how vitamin D require-
ments may vary during the life course and between popula-
tions. Opportunities to explore either acute or longer-term
interventions that may transiently change 25(OH)D
expenditure should be explored to further enhance the under-
standing of vitamin D metabolism.
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